These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37208235)

  • 1. Center-level self-study identifies opportunities to advance equity in cystic fibrosis clinical trial participation.
    Januska MN; Langfelder-Schwind E; Plachta A; Demarco T; Walker PA; Berdella MN
    J Cyst Fibros; 2023 Jul; 22(4):665-668. PubMed ID: 37208235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of disease-causing CFTR variants in state newborn screening programs.
    McGarry ME; Ren CL; Wu R; Farrell PM; McColley SA
    Pediatr Pulmonol; 2023 Feb; 58(2):465-474. PubMed ID: 36237137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minorities Are Underrepresented in Clinical Trials of Pharmaceutical Agents for Cystic Fibrosis.
    McGarry ME; McColley SA
    Ann Am Thorac Soc; 2016 Oct; 13(10):1721-1725. PubMed ID: 27410177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telehealth use in cystic fibrosis during COVID-19: Association with race, ethnicity, and socioeconomic factors.
    Albon D; Van Citters AD; Ong T; Dieni O; Dowd C; Willis A; Sabadosa KA; Scalia P; Reno K; Oates GR; Schechter MS
    J Cyst Fibros; 2021 Dec; 20 Suppl 3():49-54. PubMed ID: 34930543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations.
    Husain JM; Cromartie D; Fitzelle-Jones E; Brochier A; Borba CPC; Montalvo C
    J Subst Abuse Treat; 2023 Jan; 144():108918. PubMed ID: 36403456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators.
    Kramer-Golinkoff E; Camacho A; Kramer L; Taylor-Cousar JL
    Pediatr Pulmonol; 2022 May; 57(5):1253-1261. PubMed ID: 35170259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Under-Representation and Under-Reporting of Minoritized Racial and Ethnic Groups in Clinical Trials on Immune Checkpoint Inhibitors.
    Chua AV; Delmerico J; Sheng H; Huang XW; Liang E; Yan L; Gandhi S; Puzanov I; Jain P; Sakoda LC; Morrow GR; Ambrosone CB; Kamen C; Yao S
    JCO Oncol Pract; 2024 Aug; ():OP2400033. PubMed ID: 39173090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seroprevalence and clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis.
    Hergenroeder GE; Faino AV; Cogen JD; Genatossio A; McNamara S; Pascual M; Hernandez RE
    Pediatr Pulmonol; 2023 Sep; 58(9):2478-2486. PubMed ID: 37314149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Misunderstandings, misperceptions, and missed opportunities: Perspectives on adherence barriers from people with CF, caregivers, and CF team members.
    Eaton CK; Beachy S; McLean KA; Nicolais CJ; Bernstein R; Sáez-Clarke E; Quittner AL; Riekert KA
    Patient Educ Couns; 2020 Aug; 103(8):1587-1594. PubMed ID: 32098744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of a comprehensive pharmacy-driven immunization care process model in a pediatric cystic fibrosis clinic.
    Zobell JT; Moss J; Creelman J; Christensen R; Jensen B; Stewart J; Ameel K; Asfour F
    Pediatr Pulmonol; 2023 Apr; 58(4):1145-1151. PubMed ID: 36600452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis.
    Westhölter D; Beckert H; Straßburg S; Welsner M; Sutharsan S; Taube C; Reuter S
    J Cyst Fibros; 2021 Nov; 20(6):1072-1079. PubMed ID: 34030985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study.
    Fila L; Grandcourtova A; Bilkova A; Drevinek P
    Front Pharmacol; 2023; 14():1178009. PubMed ID: 37332357
    [No Abstract]   [Full Text] [Related]  

  • 13. Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders' consensus view.
    De Boeck K; Lee T; Amaral M; Drevinek P; Elborn JS; Fajac I; Kerem E; Davies JC
    J Cyst Fibros; 2020 Sep; 19(5):688-695. PubMed ID: 32527602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A discrete choice experiment to quantify the influence of trial features on the decision to participate in cystic fibrosis trials.
    Dobra R; Davies J; Elborn S; Kee F; Madge S; Boeri M
    J Cyst Fibros; 2024 Jan; 23(1):73-79. PubMed ID: 38042750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine.
    Januska MN; Marx L; Walker PA; Berdella MN; Langfelder-Schwind E
    J Genet Couns; 2020 Aug; 29(4):607-615. PubMed ID: 32227567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Racial and ethnic underrepresentation in dermatology clinical trials.
    Mineroff J; Nguyen JK; Jagdeo J
    J Am Acad Dermatol; 2023 Aug; 89(2):293-300. PubMed ID: 37062462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric population with cystic fibrosis in the centre of Portugal: candidates for new therapies.
    Roda J; Teixeira T; Ai Silva I; Silva TR; Ferreira R; Amaral MD; Oliveira G
    J Pediatr (Rio J); 2022; 98(2):212-217. PubMed ID: 34252371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in Care during the COVID-19 Pandemic for People with Cystic Fibrosis.
    Sanders DB; Wu R; O'Neil T; Elbert A; Petren K; Jain R; Ren CL
    Ann Am Thorac Soc; 2022 Oct; 19(10):1697-1703. PubMed ID: 35143374
    [No Abstract]   [Full Text] [Related]  

  • 19. A Scoping Review of Health Research with Racially/Ethnically Minoritized Adults with Intellectual and Developmental Disabilities.
    Williamson HJ; Chico-Jarillo TM; Sasse S; Rennie L; Etcitty JR; Howe CL; Lee MS; Armin JS
    Dev Disabil Netw J; 2023; 3(2):. PubMed ID: 37829932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barriers implementing infection prevention and control experienced by healthcare workers, people with CF and parents.
    Saiman L; Zhou JJ; Shah KS; Jiang X; Stoudemire W; Kosorok MR; Muhlebach MS;
    J Cyst Fibros; 2022 Mar; 21(2):309-315. PubMed ID: 34521595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.